[
    {
        "path": [
            907040000,
            802000000
        ],
        "contexts": [
            "and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active",
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more"
        ]
    },
    {
        "path": [
            908030000,
            907000000
        ],
        "contexts": [
            "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the",
            "the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names"
        ]
    },
    {
        "path": [
            802060000,
            802050000
        ],
        "contexts": [
            "information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.  (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.  (3) If the medicine is",
            "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating"
        ]
    },
    {
        "path": [
            907030000,
            901030000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the"
        ]
    },
    {
        "path": [
            1009020000,
            900000000
        ],
        "contexts": [
            "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the",
            "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
        ]
    },
    {
        "path": [
            1005000000,
            900000000
        ],
        "contexts": [
            "to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other",
            "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
        ]
    },
    {
        "path": [
            907020000,
            802000000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
        ]
    },
    {
        "path": [
            601150000,
            801030000
        ],
        "contexts": [
            "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            1102070000,
            1102060000
        ],
        "contexts": [
            "metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;  (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of",
            "(ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;  (e) for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time;  (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the"
        ]
    },
    {
        "path": [
            805000000,
            801000000
        ],
        "contexts": [
            "to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the",
            "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
        ]
    },
    {
        "path": [
            1008030000,
            900000000
        ],
        "contexts": [
            "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister",
            "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
        ]
    },
    {
        "path": [
            905030000,
            901030000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
        ]
    },
    {
        "path": [
            1009010000,
            900000000
        ],
        "contexts": [
            "the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch",
            "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
        ]
    },
    {
        "path": [
            1001000000,
            1007000000
        ],
        "contexts": [
            "released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic ointment, does not contain an",
            "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
        ]
    },
    {
        "path": [
            905030000,
            802000000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
        ]
    },
    {
        "path": [
            907030000,
            901020000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "(d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:  (e) where there are four or more active ingredients, the names of the active ingredients; and  (f) the quantity or proportion of all active ingredients in the medicine; and  (g) the name of the dosage form; and  (h) the quantity of the medicine in the container; and  (i) the batch number of the"
        ]
    },
    {
        "path": [
            1007000000,
            1001000000
        ],
        "contexts": [
            "released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic ointment, does not contain an",
            "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
        ]
    },
    {
        "path": [
            1009010000,
            800000000
        ],
        "contexts": [
            "the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch",
            "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the"
        ]
    },
    {
        "path": [
            910020000,
            911000000
        ],
        "contexts": [
            "2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing",
            "on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026.  (12) To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.  (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with"
        ]
    },
    {
        "path": [
            907030000,
            802000000
        ],
        "contexts": [
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more",
            "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
        ]
    },
    {
        "path": [
            903020000,
            1102090000
        ],
        "contexts": [
            "of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh",
            "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
        ]
    },
    {
        "path": [
            1102080000,
            1102040000
        ],
        "contexts": [
            "the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.  (d) for a medicine required to be prepared before use, and: (i) where the process results in a",
            "in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the"
        ]
    },
    {
        "path": [
            1008030000,
            800000000
        ],
        "contexts": [
            "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister",
            "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the"
        ]
    },
    {
        "path": [
            1102080000,
            1102020000
        ],
        "contexts": [
            "(f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and",
            "is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;  (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained"
        ]
    },
    {
        "path": [
            802050000,
            802030000
        ],
        "contexts": [
            "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,",
            "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating"
        ]
    },
    {
        "path": [
            910030000,
            913000000
        ],
        "contexts": [
            "2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing",
            "with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied"
        ]
    },
    {
        "path": [
            908030000,
            906020000
        ],
        "contexts": [
            "name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if",
            "number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the"
        ]
    },
    {
        "path": [
            302020000,
            500000000
        ],
        "contexts": [
            "Order does not apply to a medicine that is: (a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or (b) intended to be supplied to a Category A person under the exemption provided for in regulation 12A of the Regulations; or (c) the subject of an authorisation granted under subsection 19(5) of the Act and its use is consistent with the requirements set out in regulation 12B of the Regulations; or (ca) intended for use",
            "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must"
        ]
    },
    {
        "path": [
            802050000,
            802040000
        ],
        "contexts": [
            "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating",
            "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,"
        ]
    },
    {
        "path": [
            403000000,
            402000000
        ],
        "contexts": [
            "medicine to which this Order applies must comply with the requirements specified in this Order. (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). 5 Exemptions \u2013 Medicines to which this Order does not apply   This Order does not apply to a medicine that is: (a)",
            "each medicine to which this Order applies must comply with either: (a) the requirements specified in this Order; or (b) the requirements specified in: (i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or (ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017. (2) On and from 1 September 2020, each medicine to which this Order applies must comply"
        ]
    },
    {
        "path": [
            301000000,
            500000000
        ],
        "contexts": [
            "the medicine is unacceptable. (8) To avoid doubt, this section is not part of the Order. 1 Name of Order  This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of",
            "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must"
        ]
    },
    {
        "path": [
            1102080000,
            1102030000
        ],
        "contexts": [
            "the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.  (d) for a medicine required to be prepared before use, and: (i) where the process results in a",
            "(f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and"
        ]
    },
    {
        "path": [
            903020000,
            1102080000
        ],
        "contexts": [
            "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,",
            "of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh"
        ]
    },
    {
        "path": [
            802030000,
            802020000
        ],
        "contexts": [
            "ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution,",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            601150000,
            801100000
        ],
        "contexts": [
            "of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and  (k) relevant warning statements, where these are required in relation to a particular medicine or in specified circumstances applying to a particular medicine, such as the following: (i) where the medicine is for external use the required statement is \u2018Caution: Not to be Swallowed\u2019 or \u2018For External Use",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            910000000,
            909000000
        ],
        "contexts": [
            "with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied",
            "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
        ]
    },
    {
        "path": [
            1009020000,
            800000000
        ],
        "contexts": [
            "and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the",
            "of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the"
        ]
    },
    {
        "path": [
            908040000,
            906020000
        ],
        "contexts": [
            "name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if",
            "and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more"
        ]
    },
    {
        "path": [
            1103030000,
            1103020000
        ],
        "contexts": [
            "The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:  (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed",
            "to the effect that the medicine contains homoeopathic preparations in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres;  (b) the label on the container and the label on the primary pack (if any) must differentiate ingredients that are homoeopathic preparations from those that are not, such as by including the statement \u2018contains homoeopathic preparations of\u2019 adjacent to the list of homoeopathic ingredients, or by"
        ]
    },
    {
        "path": [
            903020000,
            1105000000
        ],
        "contexts": [
            "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,",
            "up by additional information or background text.  (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:  (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by"
        ]
    },
    {
        "path": [
            1007000000,
            900000000
        ],
        "contexts": [
            "is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the label on the container with sections 8 and 9 and subsection 10(1) (if applicable), it shall be sufficient if the following information is displayed in a text size of not less than 2 millimetres:  (c) the name of the medicine; and  (d) the name(s) of all active ingredients in the",
            "on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the"
        ]
    },
    {
        "path": [
            301000000,
            400000000
        ],
        "contexts": [
            "Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must",
            "the medicine is unacceptable. (8) To avoid doubt, this section is not part of the Order. 1 Name of Order  This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of"
        ]
    },
    {
        "path": [
            1008020000,
            900000000
        ],
        "contexts": [
            "the expiry date prefix; and (x) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.  (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper",
            "of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister"
        ]
    },
    {
        "path": [
            1005000000,
            800000000
        ],
        "contexts": [
            "to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other",
            "registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed goods:  (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with"
        ]
    },
    {
        "path": [
            601150000,
            801020000
        ],
        "contexts": [
            "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            903030000,
            903010000
        ],
        "contexts": [
            "up by additional information or background text.  (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:  (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by",
            "(ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.  (4) All text required by this Order to be on the main label must be oriented in the same direction.  (5) If the medicine contains:  (a) two or more active ingredients; and  (b) at least two of those active ingredients belong to any of the following"
        ]
    },
    {
        "path": [
            1103030000,
            1103010000
        ],
        "contexts": [
            "The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:  (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed",
            "or semi-solid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine; (v) where the medicine is a solid or semi-solid and includes an active ingredient which is a solid - as the weight of the active ingredient in a stated weight of the medicine.  (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary"
        ]
    },
    {
        "path": [
            601150000,
            801120000
        ],
        "contexts": [
            "information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery; \"dial dispenser pack\" means a container that has the following",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            802050000,
            802020000
        ],
        "contexts": [
            "by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating",
            "such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.  (2)  (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv)"
        ]
    },
    {
        "path": [
            908040000,
            907000000
        ],
        "contexts": [
            "the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names",
            "of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then,"
        ]
    }
]